Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva's Generic Exclusivity For Cozaar/Hyzaar Is Upheld By District Court; Apotex Appeals

This article was originally published in The Pink Sheet Daily

Executive Summary

Court finds that FDA correctly followed an appeals court's reasoning in awarding Teva exclusivity; Apotex says the agency failed to make a distinction between patent delisting and expiration.

You may also be interested in...



FDA Hit With Slew Of Suits As Firms Fight For Market Advantage

At least nine complaints have been filed against the agency since March, most involving market exclusivity claims; lawyers expect innovators will be pursuing more cases as patents expire and biosimilars emerge.

Teva Launches Generic Cozaar/Hyzaar With Market Exclusivity As FDA Seeks Court Action To Permit Other Entrants

Teva's skirmish with FDA has paid off. The company launched generic versions of Merck's top-selling hypertension drugs Cozaar (losartan) and Hyzaar (losartan/hydrochlorothiazide) on April 6 with 180 days of marketing exclusivity

Teva Launches Generic Cozaar/Hyzaar With Market Exclusivity As FDA Seeks Court Action To Permit Other Entrants

Teva's skirmish with FDA has paid off. The company launched generic versions of Merck's top-selling hypertension drugs Cozaar (losartan) and Hyzaar (losartan/hydrochlorothiazide) on April 6 with 180 days of marketing exclusivity

Topics

UsernamePublicRestriction

Register

MT142464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel